BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Nov 10, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Theraloc nimotuzumab: Preliminary Phase II/III data

Preliminary data from an ongoing, double-blind Phase II/III trial in newly-diagnosed high-grade glioma patients showed that the mean and median survival time for nimotuzumab plus radiotherapy were 14.3 and 16.4 months, respectively, compared to 8.7 and 10.5 months for placebo plus radiotherapy. The trial has enrolled...

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >